Neurocrine Biosciences, Inc. (NBIX)
128.63
-1.47
(-1.13%)
USD |
NASDAQ |
Feb 20, 16:00
128.61
-0.02
(-0.02%)
After-Hours: 20:00
Neurocrine Biosciences SG&A Expense (Quarterly) : 301.80M for Dec. 31, 2025
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Glaukos Corp. | 94.70M |
| Edgewise Therapeutics, Inc. | 9.378M |
| Nuvalent, Inc. | 28.85M |
| Marker Therapeutics, Inc. | 1.024M |
| CapsoVision, Inc. | 3.843M |